Immuneering Corp Class A IMRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $5.11
- Day Range
- $4.93–5.18
- 52-Week Range
- $2.90–10.08
- Bid/Ask
- $5.06 / $5.22
- Shares Outstanding
- 64.70M
- Market Cap
- $333.84M
- Volume/Avg
- 703,973 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 55
- Website
- https://www.immuneering.com
Valuation
|
Metric
|
IMRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.62 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMRX
|
|---|---|
Quick Ratio | 31.50 |
Current Ratio | 32.45 |
Interest Coverage | — |
Quick Ratio
IMRX
Profitability
|
Metric
|
IMRX
|
|---|---|
Return on Assets (Normalized) | −30.71% |
Return on Equity (Normalized) | −33.04% |
Return on Invested Capital (Normalized) | −34.84% |
Return on Assets
IMRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G&$#Kj^ | LOCK|Qj@< | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Q^V@jLB | LOCK|#DxD$ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|#k#zG?# | LOCK|BFW | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|SD>yD# | LOCK|nC^<l | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|m<tJGV | LOCK|>dl | $36B | |||
| Moderna Inc
MRNA
| LOCK|zR&c<@ | LOCK|w<D | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|YQ$gV&$N | LOCK|cXG$D | $25B | |||
| Incyte Corp
INCY
| LOCK|fVgL&@ | LOCK|$Cm | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|F%>$W# | LOCK|CM# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$P&%%hg | LOCK|JN | $16B |
United States